...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
Reply New Message
Back To Forum List View
Icon president Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
5
BearDownAZ
Jun 21, 2022 08:03AM

Question to the board,

 

With all this very positive science news coming from Zenith over the past several years , What are the BP's waiting for to lock in this epigenetic  technology  in a  full 100% partnership or buyout???   What are the BP's  waiting  for one of their peers to take a leap first?? or more data for confirmation....

5 Recommendations
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
2
KayakerBC
Jun 21, 2022 11:57AM
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

narmac
Jun 22, 2022 07:19AM
Icon president Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
4
Nextblockbuster
Jun 22, 2022 10:40AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply